Inna Khodos

1.9k total citations
17 papers, 614 citations indexed

About

Inna Khodos is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Inna Khodos has authored 17 papers receiving a total of 614 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 9 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Inna Khodos's work include Lung Cancer Treatments and Mutations (8 papers), Cancer Genomics and Diagnostics (5 papers) and Sarcoma Diagnosis and Treatment (3 papers). Inna Khodos is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Cancer Genomics and Diagnostics (5 papers) and Sarcoma Diagnosis and Treatment (3 papers). Inna Khodos collaborates with scholars based in United States, United Kingdom and Japan. Inna Khodos's co-authors include Elisa de Stanchina, Charles M. Rudin, Natasha Rekhtman, Linde A. Miles, Patrice Desmeules, Valentina E. Schneeberger, Julien Sage, Ai Ni, Afshin Dowlati and Scott Ribich and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Cell and Cancer Research.

In The Last Decade

Inna Khodos

16 papers receiving 600 citations

Peers

Countries citing papers authored by Inna Khodos

Since Specialization

Citations

This map shows the geographic impact of Inna Khodos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inna Khodos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inna Khodos more than expected).

Fields of papers citing papers by Inna Khodos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inna Khodos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inna Khodos. The network helps show where Inna Khodos may publish in the future.

Co-authorship network of co-authors of Inna Khodos

This figure shows the co-authorship network connecting the top 25 collaborators of Inna Khodos. A scholar is included among the top collaborators of Inna Khodos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inna Khodos. Inna Khodos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor 2024 ·Clinical Cancer Research ·(unknown), Christopher A. Febres‐Aldana, Zebing Liu, (unknown), (unknown), Raymond G. Dematteo, (unknown), Inna Khodos, (unknown), Marissa S. Mattar, (unknown), (unknown), Irina Linkov, (unknown), Elisa de Stanchina, Igor Odintsov, Marc Ladanyi, Romel Somwar	6
2	Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and MDM2 Amplification 2024 ·JCO Precision Oncology ·Arielle Elkrief, Igor Odintsov, Roger S. Smith, Morana Vojnic, Takuo Hayashi, Inna Khodos, Vladimir Markov, Zebing Liu, (unknown), (unknown), Michael Offin, Charles M. Rudin, Elisa de Stanchina, Gregory J. Riely, Romel Somwar, Marc Ladanyi	3
3	Abstract B157: Preclinical evaluation of the blood-brain barrier permeability and intracranial efficacy of the next-generation RET inhibitor Vepafestinib 2023 ·Molecular Cancer Therapeutics ·Igor Odintsov, (unknown), (unknown), (unknown), Masanori Kato, (unknown), Inna Khodos, Morana Vojnic, Claudio Giuliano, Annalisa Bonifacio, Monika A. Davare, Elisa de Stanchina, Emanuela Lovati, Marc Ladanyi, Isao Miyazaki, Romel Somwar	1
4	Prospective Clinical Genomic Profiling of Ewing Sarcoma: ERF and FGFR1 Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic Relevance 2022 ·JCO Precision Oncology ·Koichi Ogura, Arielle Elkrief, Anita S. Bowman, Richard P. Koche, Elisa de Stanchina, Ryma Benayed, Audrey Mauguen, Marissa S. Mattar, Inna Khodos, Paul A. Meyers, John H. Healey, William D. Tap, Meera Hameed, Ahmet Zehir, Neerav Shukla, Charles L. Sawyers, Rohit Bose, Emily K. Slotkin, Marc Ladanyi	6
5	Comparison of TAS0953/HM06 and selpercatinib in RET fusion-driven preclinical disease models of intracranial metastases. 2022 ·Journal of Clinical Oncology ·Igor Odintsov, (unknown), Kota Ishizawa, Isao Miyazaki, Inna Khodos, (unknown), Morana Vojnic, (unknown), Qing Chang, Annalisa Bonifacio, Claudio Giuliano, Elisa de Stanchina, Emanuela Lovati, Emily H. Cheng, Marc Ladanyi, Romel Somwar	8
6	The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions 2021 ·Clinical Cancer Research ·Igor Odintsov, (unknown), (unknown), (unknown), Zebing Liu, Lukas Delasos, (unknown), (unknown), Morana Vojnic, Inna Khodos, Marissa S. Mattar, Elisa de Stanchina, (unknown), Marc Ladanyi, Romel Somwar	31
7	Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers 2021 ·Journal of Thoracic Oncology ·Igor Odintsov, Marissa S. Mattar, (unknown), Michael Offin, (unknown), Lukas Delasos, Inna Khodos, Marina Asher, (unknown), Natasha Rekhtman, Elisa de Stanchina, Gopinath Ganji, Marc Ladanyi, Romel Somwar	21
8	Abstract P233: TAS0953/HM06 is effective in preclinical models of diverse tumor types driven by RET alterations 2021 ·Molecular Cancer Therapeutics ·Igor Odintsov, (unknown), Kota Ishizawa, Lukas Delasos, (unknown), Inna Khodos, (unknown), Qing Chang, Marissa S. Mattar, Morana Vojnic, Siddharth Kunte, Annalisa Bonifacio, Claudio Giuliano, Elisa de Stanchina, Emily H. Cheng, Emanuela Lovati, Marc Ladanyi, Romel Somwar	5
9	Abstract 956: The HER2×HER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions 2021 ·Cancer Research ·Igor Odintsov, Inna Khodos, (unknown), (unknown), Marissa S. Mattar, Alison M. Schram, Ron C.J. Schackmann, Jeroen Lammerts van Bueren, Cecile Geuijen, Elisa de Stanchina, Marc Ladanyi, Romel Somwar	1
10	Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor 2020 ·Clinical Cancer Research ·Koichi Ogura, Romel Somwar, Julija Hmeljak, Heather Magnan, Ryma Benayed, Amir Momeni Boroujeni, Anita S. Bowman, Marissa S. Mattar, Inna Khodos, Elisa de Stanchina, Achim A. Jungbluth, Marina Asher, Igor Odintsov, (unknown), Michael P. LaQuaglia, Emily K. Slotkin, Christine A. Pratilas, Sean Bong Lee, Lee Spraggon, Marc Ladanyi	24
11	NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors 2020 ·Communications Biology ·Romel Somwar, Nicolle E. Hofmann, Bryan D. Smith, Igor Odintsov, Morana Vojnic, Irina Linkov, (unknown), Inna Khodos, Marissa S. Mattar, Elisa de Stanchina, Daniel L. Flynn, Marc Ladanyi, Alexander Drilon, Ujwal Shinde, Monika A. Davare	41
12	Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer 2018 ·Clinical Cancer Research ·Ken Suzawa, Michael Offin, Daniel Lu, (unknown), Morana Vojnic, Roger S. Smith, Joshua K. Sabari, Huichun Tai, Marissa S. Mattar, Inna Khodos, Elisa de Stanchina, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, William W. Lockwood, Alexander Drilon, Marc Ladanyi, Romel Somwar	83
13	Abstract 1826: Oncogenic KRAS mediates resistance to MET targeted therapy in non-small cell lung cancer (NSCLC) with MET mutations that induce exon14 skipping 2018 ·Cancer Research ·Ken Suzawa, Michael Offin, (unknown), Daniel Liu, Morana Vojnic, Roger S. Smith, Marissa S. Mattar, Inna Khodos, Elisa de Stanchina, Joshua K. Sabari, William W. Lockwood, Alexander Drilon, Marc Ladanyi, Romel Somwar	0
14	Acquired BRAF fusions as a mechanism of resistance to EGFR therapy. 2018 ·Journal of Clinical Oncology ·Morana Vojnic, (unknown), Daisuke Kubota, Ken Suzawa, Zebing Liu, Marissa S. Mattar, Inna Khodos, John T. Poirier, Elisa de Stanchina, Charles M. Rudin, Gregory J. Riely, Helena A. Yu, Maria E. Arcila, Marc Ladanyi, Romel Somwar	2
15	Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis 2017 ·Cancer Cell ·Eric E. Gardner, Benjamin H. Lok, Valentina E. Schneeberger, Patrice Desmeules, Linde A. Miles, Paige K. Arnold, Ai Ni, Inna Khodos, Elisa de Stanchina, Thuyen Nguyen, Julien Sage, John E. Campbell, Scott Ribich, Natasha Rekhtman, Afshin Dowlati, Pierre P. Massion, Charles M. Rudin, John T. Poirier	347
16	MDM2 amplification (Amp) to mediate cabozantinib resistance in patients (Pts) with advanced RET-rearranged lung cancers. 2016 ·Journal of Clinical Oncology ·Romel Somwar, Roger S. Smith, Takuo Hayashi, Kota Ishizawa, Alexandra Snyder, Inna Khodos, Marissa S. Mattar, Jie He, Sohail Balasubramanian, Phil Stephens, Doron Lipson, Elisa de Stanchina, Monika A. Davare, Vincent A. Miller, Gregory J. Riely, Charles M. Rudin, Mark G. Kris, Emily H. Cheng, Marc Ladanyi, Alexander Drilon	19
17	A Novel Dietary Supplement Containing Multiple Phytochemicals and Vitamins Elevates Hepatorenal and Cardiac Antioxidant Enzymes in the Absence of Significant Serum Chemistry and Genomic Changes 2010 ·Oxidative Medicine and Cellular Longevity ·(unknown), (unknown), Payal Patel, (unknown), Tejas S. Lahoti, Inna Khodos, S.J. Stohs, Sidhartha D. Ray	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact